Orexigen revises obesity drug's positive results

Orexigen's stock price slipped on news that results from a Phase III trial of its anti-obesity drug Contrave weren't as positive as originally reported. The company had said that 56.3 percent of patients taking Contrave lost 5 percent or more of their body weight, but that number was actually 50.5. Additionally, only 28.3 percent of users lost more than 10 percent of their weight, down from 32.9 percent. The incorrect numbers were the result of a clerical error. Orexigen was quick to point out that the study still met its primary endpoint.

Contrave is a sustained-release version of two existing drugs--the antidepressant Wellbutrin and alcoholism treatment naltrexone. Orexigen filed an NDA for the drug on March 31. The company is in a race with two other developers--Arena Pharmaceuticals and Vivus--to gain approval of a new therapy for largely-untapped obesity market.

- read the Reuters report for more

Suggested Articles

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.

After culling a $2.6 billion biobucks pact last year, Bristol Myers Squibb is making a second and final cut to its pact with I-O biotech Jounce.

With its $400 million Fund XII, Atlas Venture became the latest VC shop to close a major fund since the WHO officially declared COVID-19 a pandemic.